1. Show article details.

    Accelmed Launches Accelmed Ventures II, a New $100 Million Venture HealthTech Fund

    PR Newswire – 8:19 AM ET 10/07/2019

    HERZLIYA, Israel, Oct. 7, 2019  Accelmed, a group of funds investing in healthtech companies in the fields of medical device and digital health, announced today that it is establishing Accelmed Ventures II, a new venture capital fund with the goal of raising and managing approximately $100 million.

  2. Show article details.

    Accelmed seeks to raise $100 mln for fourth health tech fund

    Reuters – 4:24 AM ET 10/07/2019

    Accelmed, a U.S.-Israel group of funds investing in medical device and digital health companies, said on Monday it was establishing a new fund with the aim of raising and managing $100 million. The Accelmed Ventures II fund will invest in Israeli and global pre-revenue health tech startups.

  3. AngioDynamics stock price target cut to $21 from $30 at KeyBanc Capital

    MarketWatch – 7:29 AM ET 10/04/2019
  4. Show article details.

    BRIEF-Angiodynamics Acquires Eximo Medical, Ltd. And Its Innovative 355Nm Laser Atherectomy Technology

    Reuters – 6:15 AM ET 10/03/2019

    AngioDynamics Inc (ANGO): * ANGIODYNAMICS ACQUIRES EXIMO MEDICAL, LTD. AND ITS INNOVATIVE 355NM LASER ATHERECTOMY TECHNOLOGY. * AngioDynamics Inc (ANGO) - TRANSACTION IS BEING FUNDED EXCLUSIVELY THROUGH USE OF CASH ON HAND. * AngioDynamics Inc (ANGO) - TRANSACTION IS BEING FUNDED EXCLUSIVELY THROUGH USE OF CASH ON HAND.

  5. Show article details.

    BRIEF-Angiodynamics Q1 Adjusted Earnings Per Share $0.08

    Reuters – 6:11 AM ET 10/03/2019

    AngioDynamics Inc (ANGO): * ANGIODYNAMICS REPORTS FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS. * Q1 ADJUSTED EARNINGS PER SHARE $0.08. * Q1 LOSS PER SHARE $0.03 FROM CONTINUING OPERATIONS. * Q1 SALES $66 MILLION VERSUS REFINITIV IBES ESTIMATE OF $67.5 MILLION. * Q1 EARNINGS PER SHARE ESTIMATE $0.04 -- REFINITIV IBES DATA. * SEES FY 2020 SALES $280 MILLION TO $286 MILLION.

  6. Show article details.

    AngioDynamics Reports Fiscal 2020 First Quarter Financial Results

    Business Wire – 6:02 AM ET 10/03/2019

    Fiscal 2020 First Quarter Highlights LATHAM, N.Y.---- AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the first quarter of fiscal year 2020, which ended August 31, 2019.

  7. Show article details.

    AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology

    Business Wire – 6:00 AM ET 10/03/2019

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of con...

  8. Show article details.

    AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement

    Business Wire – 8:00 AM ET 09/09/2019

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing agreement by Premier, Inc. to supply implantable infusion ports.

  9. Show article details.

    AngioDynamics to Report Fiscal 2020 First Quarter Financial Results on October 3, 2019

    Business Wire – 4:01 PM ET 09/05/2019

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2020 before the market open on Thursday, October 3, 2019.

  10. Show article details.

    AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors

    Business Wire – 4:01 PM ET 07/31/2019

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the appointment of Karen Licitra to its board of directors as a Class III director, effective July 17, 2019.

  11. Show article details.

    AngioDynamics to Present at the Canaccord Genuity Growth Conference

    Business Wire – 4:01 PM ET 07/23/2019

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the 39th Annual Canaccord Genuity Growth Conference at 10:30 a.m. ET on Wednesday, August 7, 2019 in Boston, MA. A live webcast of the presentation will b...

Page:

Today's and Upcoming Events

  • Jan
    02

    ANGO to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Oct
    03

    ANGO announced Q1 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.